Jaguar Health Inc. $(JAGX)$ has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi (crofelemer 125mg delayed-release tablets), used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.